An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes

Acta Diabetologica

Volumn 52, Issue 5, 2015, Pages 881-888

  Snarski, Emilian ^a   Szmurło, Daria ^a   Hałaburda, Kazimierz ^b   Król, Małgorzata ^a   Urbanowska, Elżbieta ^a   Milczarczyk, Alicja ^c   Franek, Edward ^c,d   Wiktor Jedrzejczak, Wiesław ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^c Central Hospital   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cost effectiveness; Diabetes; Stem cell; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN A1C; INSULIN; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STEM CELL MOBILIZATION; SURVIVAL RATE; AUTOTRANSPLANTATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INSULIN; MALE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84941944365     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-015-0724-1     Document Type: Article

References (27)

1. Dall TM, Mann SE, Zhang Y, Quick WW, Seifert RF, Martin J et al (2009) Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 12(2):103–110
2. Efstathiou E, Skordis N (2011) Altering trends in the epidemiology of type 1 diabetes mellitus in children and adolescents. In: Liu C-P (ed) Type 1 diabetes—complications, pathogenesis, and alternative treatments. InTech, Rijeka
3. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F et al (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297:1568–1576
4. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M et al (2011) Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type 1. Bone Marrow Transplant 46(4):562–566
5. Zhang X, Ye L, Hu J, Tang W, Liu R, Yang M et al (2012) Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS One 7(2):e31887
6. Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W et al (2012) Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 97(5):1729–1736
7. Gu W, Hu J, Wang W, Li L, Tang W, Sun S et al (2012) Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care 35(7):1413–1419
8. Fiorina P, Voltarelli J, Zavazava N (2011) Immunological applications of stem cells in type 1 diabetes. Endocr Rev 32(6):725–754
9. Francese R, Fiorina P (2010) Immunological and regenerative properties of cord blood stem cells. Clin Immunol 136(3):309–322
10. D’Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L et al (2014) Autologous non-myeloablative hematopoietic stem cell transplantation in new onset type 1 diabetes: a multicenter analysis. Diabetes 63(9):3041–3046
11. Khera N, Zeliadt SB, Lee SJ (2012) Economics of hematopoietic cell transplantation. Blood 120(8):1545–1551
12. Seber A (2012) The cost of hematopoietic stem cell transplantation in the real world. Hematolog. 17(Suppl 1):S208–S211
13. Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 45(6):1014–1021
14. CORE Diabetes Model web page www.core-diabetes.com
15. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM et al (2004) The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 20(Suppl 1):S5–S26
16. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986
17. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33. Lancet 352(9131):837–853
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589
19. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038
20. Grant D, Foos V, Palmer J, Lloyd A, Evans M, Mcewan P (2012) Long-term validation of the IMS CORE Diabetes Model in type 1 and type 2 diabetes. 72nd Scientific Sessions, American Diabetes Association, Philadelphia
21. AOTM—Agency for Health Technology Assessment. Guidelines for conducting Health Technology Assessment (HTA) Version 2.1 Warsaw, April 2009 Avalable at http://www.aotm.gov.pl/assets/files/wytyczne_hta/2009/09.06.29_wytyczne_HTA_eng_MS.pdf
22. Beaudet A, Clegg JP, Lloyd A (2012) PDB54 systematic literature review of utility values associated with type 2 diabetes-related complications. Value Health 15(7):A503
23. Witek PW, Wołkow P, Stancel-Możwiłło J, Wojtyczek K, Sieradzki J, Małecki M (2012) The polish diabetes registry for adults—a pilot study. Diabetologia Kliniczna 1(1):3–11
24. Andel M, Grzeszczak W, Michalek J, Medvescek M, Norkus A, Rasa I, DEPAC Group et al (2008) A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey). Diabetic Med 25(10):1195–1203
25. Reimbursement List 01.2014 (http://www2.mz.gov.pl/wwwmz/index?mr=m111111&ms=&ml=pl&mi=&mx=0&mt=&my=&ma=033091)
26. Szmurło D, Schubert A, Kostrzewska K, Ryś P, Skrzekowska-Baran I (2011) Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland. What increase in costs is justified by clinical results? Pol Arch Med Wewn 121(10):345–351
27. Dave SD, Trivedi LH, Chooramani SG, Chandra T (2013) Management of type 1 diabetes mellitus using invitro autologous adipose tissue trans-differentiated insulin-making cells. BMJ Case Rep. doi:10.1136/bcr-2013-200226